 |
 |
Date Announced: 28 Jan 2025
Melles Griot and Semrock product lines likely to feature in new proteomics platform.
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and IDEX Health & Science, LLC., today announced they will partner on the development and manufacturing of the optics module for Quantum-Si’s novel proteomics platform, Proteus™.
IDEX Health & Science, LLC is the global leader in life science optics, fluidics and microfluidics, offering a three-fold advantage to customers by bringing optofluidic paths to life with strategic partnerships, breakthrough solutions, and proven expertise. Through the Melles Griot and Semrock product lines, IDEX Health & Science offers the broadest and most complete solution to support customer optical needs. From stand-alone lasers, optics, optical filter components, and pre-aligned optics and photonics modules, to R&D and design capabilities, through to scalable manufacturing capabilities in an ISO9001 facility. In this partnership, IDEX Health & Science will support the design and development of the Proteus optics module and serve as the manufacturer.
“We are thrilled to enter into this partnership with IDEX Health & Science and leverage their industry leading expertise in the development and manufacturing of complex optical systems for life sciences instrumentation,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “Being able to have IDEX Health & Science’s unique experience and world class technical team involved in the Proteus instrument program at this key phase of development, further increases our confidence in delivering this novel platform to market by the second half of 2026.”
“IDEX Health & Science is excited to partner with Quantum-Si in the development of their innovative proteomics platform,” said Carlos Sevilla, Vice President and General Manager of Life Science Optics at IDEX Health & Science. “As the world leader in designing and manufacturing cutting-edge optical, laser, and photonics components and systems, we collaborate closely with our customers to accelerate their scientific advancements. From initial design to final manufacturing, we effectively mitigate risks associated with timelines and critical product launches. By collaborating with the Quantum-Si team in developing their new proteomics platform we aim to further empower breakthroughs in drug discovery, diagnostics, and human health.”
Source: Quantum-Si
E-mail: support@quantum-si.com
Web Site: www.quantum-si.com
| © 2025 SPIE Europe |
|
